Patrick Schreiner

Patrick Schreiner

Auto-generated profile, based on publicly available information

Patrick Schreiner

Center for Applied Bioinformatics, St. Jude Children’s Research Hospital, Memphis, TN, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BGBryan R. Gorman
Bryan R. Gorman
GVGeorgios Voloudakis
Georgios Voloudakis
RIRobert P. Igo
Robert P. Igo
TKTyler Kinzy
Tyler Kinzy
CHChristopher W. Halladay
Christopher W. Halladay
SISudha K. Iyengar
Sudha K. Iyengar

15 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMadeline B. Searcy
Madeline B. Searcy
RLRandolph K. Larsen
Randolph K. Larsen
BSBradley T. Stevens
Bradley T. Stevens
YZYang Zhang
Yang Zhang
HJHongjian Jin
Hongjian Jin
MHMark Hatley
Mark Hatley
Fusion-positive rhabdomyosarcoma (FP-RMS) driven by the expression of the PAX3-FOXO1 (P3F) fusion oncoprotein is an aggressive subtype of pediatric rhabdomyosarcoma. FP-RMS histologically resembles developing muscle yet occurs throughout the body in areas devoid of skeletal muscle highlighting that FP-RMS is not derived from an exclusively myogenic cell of origin. Here we demonstrate that P3F reprograms mouse and human endothelial progenitors to FP-RMS. We show that P3F expression in aP2-Cre expressing cells reprograms endothelial progenitors to functional myogenic stem cells capable of regenerating injured muscle fibers. Further, we describe a FP-RMS mouse model driven by P3F expression and Cdkn2a loss in endothelial cells. Additionally, we show that P3F expression in TP53-null human iPSCs blocks endothelial-directed differentiation and guides cells to become myogenic cells that form FP-RMS tumors in immunocompromised mice. Together these findings demonstrate that FP-RMS can originate from aberrant development of non-myogenic cells driven by P3F.

15 October 2021 in Neuron
Verified
Journal Article
Closed access
ADAditi
Aditi
SDSusanna M. Downing
Susanna M. Downing
PSPatrick A. Schreiner
Patrick A. Schreiner
YKYoung Don Kwak
Young Don Kwak
YLYang Li
Yang Li
PMPeter J. McKinnon
Peter J. McKinnon

1 February 2021 in eLife
Verified
Journal Article
Open access
BLBrandon R Lowe
Brandon R Lowe
RYRajesh K Yadav
Rajesh K Yadav
RHRyan A Henry
Ryan A Henry
PSPatrick Schreiner
Patrick Schreiner
AMAtsushi Matsuda
Atsushi Matsuda
JPJanet Partridge
Janet Partridge
Sequencing of cancer genomes has identified recurrent somatic mutations in histones, termed oncohistones, which are frequently poorly understood. Previously we showed that fission yeast expressing only the H3.3G34R mutant identified in aggressive pediatric glioma had reduced H3K36 trimethylation and acetylation, increased genomic instability and replicative stress, and defective homology-dependent DNA damage repair. Here we show that surprisingly distinct phenotypes result from G34V (also in glioma) and G34W (giant cell tumors of bone) mutations, differentially affecting H3K36 modifications, subtelomeric silencing, genomic stability; sensitivity to irradiation, alkylating agents, and hydroxyurea; and influencing DNA repair. In cancer, only 1 of 30 alleles encoding H3 is mutated. Whilst co-expression of wild-type H3 rescues most G34 mutant phenotypes, G34R causes dominant hydroxyurea sensitivity, homologous recombination defects, and dominant subtelomeric silencing. Together, these studies demonstrate the complexity associated with different substitutions at even a single residue in H3 and highlight the utility of genetically tractable systems for their analysis.

24 January 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
YSYongwei Su
Yongwei Su
JCJenna L. Carter
Jenna L. Carter
XLXinyu Li
Xinyu Li
YFYu Fukuda
Yu Fukuda
AGAshley Gray
Ashley Gray
Yubin GeYubin Ge
Yubin Ge
Eradication of acute myeloid leukemia (AML) is therapeutically challenging; many patients succumb to AML despite initially responding to conventional treatments. Here, we showed that the imipridone ONC213 elicits potent antileukemia activity in a subset of AML cell lines and primary patient samples, particularly in leukemia stem cells, while producing negligible toxicity in normal hematopoietic cells. ONC213 suppressed mitochondrial respiration and elevated α-ketoglutarate by suppressing α-ketoglutarate dehydrogenase (αKGDH) activity. Deletion of OGDH, which encodes αKGDH, suppressed AML fitness and impaired oxidative phosphorylation, highlighting the key role for αKGDH inhibition in ONC213-induced death. ONC213 treatment induced a unique mitochondrial stress response and suppressed de novo protein synthesis in AML cells. Additionally, ONC213 reduced the translation of MCL1, which contributed to ONC213-induced apoptosis. Importantly, a patient-derived xenograft from a relapsed AML patient was sensitive to ONC213 in vivo. Collectively, these findings support further development of ONC213 for treating AML. Significance: In AML cells, ONC213 suppresses αKGDH, which induces a unique mitochondrial stress response, and reduces MCL1 to decrease oxidative phosphorylation and elicit potent antileukemia activity. See related commentary by Boët and Sarry, p. 950

25 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MFMichael Francis
Michael Francis
BGBryan R. Gorman
Bryan R. Gorman
TBTim B. Bigdeli
Tim B. Bigdeli
GGGiulio Genovese
Giulio Genovese
GVGeorgios Voloudakis
Georgios Voloudakis
SPSaiju Pyarajan
Saiju Pyarajan
Mosaic loss of chromosome Y (mLOY) is the most commonly detected mosaic chromosomal alteration, and is associated with a range of health outcomes in males. We detected mLOY in 106,054 European (EUR), 13,927 admixed African (AFR), and 6,127 Hispanic (HIS) participants of the Million Veteran Program (MVP; Ntotal=544,112). mLOY was positively associated with cigarette smoking, and negatively with obesity and type 2 diabetes. Multi-ancestry genome-wide association meta-analysis of MVP and UK Biobank mLOY summary statistics, jointly comprising 167,899 cases and 581,224 controls, identified 380 independent risk loci—240 of which were novel. GWAS in MVP high cell fraction (CF>10%) mLOY cases exhibited stronger effect sizes across risk loci. Local-ancestry-aware GWAS resolved ancestry-specific signals at BCL2L1 and SETBP1. Integrative eQTL analyses highlighted 51 genes that causally influence mLOY via differential expression. Finally, traits with genetic correlations and polygenic scores significantly associated with mLOY were selected for Mendelian randomization (MR), implicating thirteen traits as causal influences on mLOY, including triglycerides, high-density lipoprotein, and body mass index.